Medtech availability a factor in Canadian wait time plan
This article was originally published in Clinica
Executive Summary
The Canadian Wait Time Alliance (WTA), consisting of six specialty medical associations, has released an interim report on what it considers to be medically acceptable wait times. The report sets out "first principles" to benchmark the setting of wait-times for cardiac care, cancer care, diagnostic imaging, joint replacement and sight restoration, areas prioritised in the first ministers' 2004 10-year plan.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.